|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LIF |
Gene summary for LIF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LIF | Gene ID | 3976 |
| Gene name | LIF interleukin 6 family cytokine | |
| Gene Alias | CDF | |
| Cytomap | 22q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P15018 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3976 | LIF | P21T-E | Human | Esophagus | ESCC | 2.23e-02 | 2.90e-01 | 0.1617 |
| 3976 | LIF | P57T-E | Human | Esophagus | ESCC | 2.26e-03 | 6.81e-01 | 0.0926 |
| 3976 | LIF | P74T-E | Human | Esophagus | ESCC | 1.79e-05 | 1.04e-01 | 0.1479 |
| 3976 | LIF | P75T-E | Human | Esophagus | ESCC | 7.01e-08 | 3.69e-01 | 0.1125 |
| 3976 | LIF | P76T-E | Human | Esophagus | ESCC | 1.52e-10 | 6.13e-01 | 0.1207 |
| 3976 | LIF | P83T-E | Human | Esophagus | ESCC | 3.19e-20 | 1.07e+00 | 0.1738 |
| 3976 | LIF | P130T-E | Human | Esophagus | ESCC | 1.15e-02 | 2.11e-01 | 0.1676 |
| 3976 | LIF | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 2.79e-03 | 5.63e-01 | -0.1433 |
| 3976 | LIF | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 5.90e-08 | 8.82e-01 | -0.1833 |
| 3976 | LIF | 047563_1562-all-cells | Human | Prostate | BPH | 1.89e-02 | 2.56e-01 | 0.0791 |
| 3976 | LIF | 048752_1579-all-cells | Human | Prostate | BPH | 4.61e-05 | 1.95e-01 | 0.1008 |
| 3976 | LIF | Dong_P1 | Human | Prostate | Tumor | 7.45e-29 | 4.30e-01 | 0.035 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
| GO:1903829111 | Esophagus | ESCC | positive regulation of cellular protein localization | 199/8552 | 276/18723 | 2.99e-19 | 3.45e-17 | 199 |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:190018018 | Esophagus | ESCC | regulation of protein localization to nucleus | 102/8552 | 136/18723 | 2.84e-12 | 1.13e-10 | 102 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:190018217 | Esophagus | ESCC | positive regulation of protein localization to nucleus | 70/8552 | 87/18723 | 2.63e-11 | 8.99e-10 | 70 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:0010639110 | Esophagus | ESCC | negative regulation of organelle organization | 215/8552 | 348/18723 | 8.20e-10 | 2.01e-08 | 215 |
| GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
| GO:003105614 | Esophagus | ESCC | regulation of histone modification | 106/8552 | 152/18723 | 1.52e-09 | 3.55e-08 | 106 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| hsa046688 | Prostate | BPH | TNF signaling pathway | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
| hsa0466815 | Prostate | BPH | TNF signaling pathway | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
| hsa0466821 | Prostate | Tumor | TNF signaling pathway | 40/1791 | 114/8465 | 3.88e-04 | 2.07e-03 | 1.29e-03 | 40 |
| hsa0466831 | Prostate | Tumor | TNF signaling pathway | 40/1791 | 114/8465 | 3.88e-04 | 2.07e-03 | 1.29e-03 | 40 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Breast | DCIS |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Breast | Healthy |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Breast | Healthy |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Cervix | ADJ |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Cervix | CC |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Cervix | CC |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Cervix | Precancer |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Endometrium | ADJ |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Endometrium | ADJ |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Endometrium | AEH |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Endometrium | AEH |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Endometrium | EEC |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Endometrium | EEC |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Endometrium | Healthy |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Endometrium | Healthy |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | Esophagus | ESCC |
| LIF | LIFR_IL6ST | LIF_LIFR_IL6ST | LIFR | Esophagus | ESCC |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | HNSCC | ADJ |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | HNSCC | Healthy |
| OSM | LIFR_IL6ST | OSM_LIFR_IL6ST | OSM | HNSCC | OSCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LIF | SNV | Missense_Mutation | rs753939297 | c.451G>A | p.Val151Met | p.V151M | P15018 | protein_coding | tolerated(0.09) | probably_damaging(0.997) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LIF | SNV | Missense_Mutation | c.102T>G | p.Cys34Trp | p.C34W | P15018 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AR-A0TP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| LIF | SNV | Missense_Mutation | novel | c.344N>G | p.Ser115Cys | p.S115C | P15018 | protein_coding | deleterious(0.01) | possibly_damaging(0.627) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| LIF | SNV | Missense_Mutation | novel | c.343N>A | p.Ser115Thr | p.S115T | P15018 | protein_coding | deleterious(0.02) | benign(0.029) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| LIF | SNV | Missense_Mutation | rs140799590 | c.218N>T | p.Pro73Leu | p.P73L | P15018 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| LIF | SNV | Missense_Mutation | c.514N>T | p.Thr172Ser | p.T172S | P15018 | protein_coding | tolerated(0.58) | benign(0.023) | TCGA-G4-6293-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | SD | |
| LIF | SNV | Missense_Mutation | novel | c.576G>T | p.Lys192Asn | p.K192N | P15018 | protein_coding | tolerated(0.08) | probably_damaging(0.996) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| LIF | SNV | Missense_Mutation | novel | c.575A>C | p.Lys192Thr | p.K192T | P15018 | protein_coding | tolerated(0.14) | probably_damaging(0.996) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| LIF | SNV | Missense_Mutation | novel | c.143N>G | p.Ile48Ser | p.I48S | P15018 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| LIF | SNV | Missense_Mutation | rs746660268 | c.421N>A | p.Ala141Thr | p.A141T | P15018 | protein_coding | tolerated(1) | benign(0.015) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | RETINOIC ACID | 2119291 | ||
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | HORMONES | 11589623 | ||
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | BUPIVACAINE | BUPIVACAINE | 10838161 | |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | CLOMIPHENE CITRATE | 12012626 | ||
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | PACLITAXEL | PACLITAXEL | 11800022 | |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | IL-13 | 12620497 | ||
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | SIMVASTATIN | SIMVASTATIN | 16797728 | |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | CISPLATIN | CISPLATIN | 11800022,12519017 | |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | MIFEPRISTONE | MIFEPRISTONE | 10717784 | |
| 3976 | LIF | GROWTH FACTOR, DRUGGABLE GENOME | OESTRADIOL | ESTRADIOL | 10508216 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |